SynthesisScientific reports2025
Circulating MiRNAs as diagnostic biomarkers of lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- miR-155-3p in Systemic Lupus Erythematosus: Association with Immune Activation and Renal-Related Parameters.Applied biochemistry and biotechnology · 2026Article
- MicroRNAs as current diagnostic biomarkers and potential therapeutic targets in allergic and non-allergic rhinitis - A functional characterization.Current allergy and asthma reports · 2026Review
- Affinity Peptide-Based Circularly Permuted Fluorescent Protein Biosensors Loaded in a Microfluidic System for Systemic Lupus Erythematosus Diagnosis.Sensors (Basel, Switzerland) · 2026Article
- Platelet-derived non-coding RNAs as emerging contributors to autoimmune inflammation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- miRNAs in Glomerular Diseases: From Pathogenic Insight to Therapeutic Potential: A Narrative Review.Cells · 2026Review
- TRIM8-associated non-coding RNA panel as a biomarker for Lupus nephritis activity.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Managing lupus nephritis (LN) has been challenging despite therapeutic advancements, as 30% of patients face end-stage kidney disease. Current laboratory tests for diagnosing LN activity are insufficient. Recognizing the potential for severe complications in patients with LN, there is crucial need to identify innovative biomarkers for early diagnosis of this disease. Hence, the objective of this study was to evaluate diagnostic efficacy of miRNAs for LN. The protocol has been registered on PROSPERO (CRD42023460747). This systematic review and meta-analysis was performed following the PRISMA guidelines. A comprehensive search for relevant literature was carried out across PubMed, Scopus, Embase, and Hinari. The methodological quality of the articles was assessed using the QUADAS-2 tool. Stata 14.0 software was used to calculate pooled sensitivity, specificity, and other diagnostic parameters related to miRNAs for the diagnosis of LN utilizing a random effects model. The assessment of heterogeneity among studies involved the application of the Cochran-Q test and I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.